WallStSmart
RGC

Regencell Bioscience Holdings Ltd

NASDAQ: RGC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$31.47
-9.79% today

Updated 2026-06-05

Market cap
$10.28B
P/E ratio
P/S ratio
EPS (TTM)
$-0.01
Dividend yield
52W range
$9 – $84
Volume
0.1M

Regencell Bioscience Holdings Ltd (RGC) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-806.06%
ROA
-85.00%
Debt/equity
0.32x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$2.52B$91.00M96.18%10.69%3.62%
2007$2.60B$86.00M96.00%11.86%3.31%
2008$2.66B$363.00M96.13%12.10%13.64%
2009$2.77B$72.00M96.17%10.25%2.60%
2010$2.89B$95.50M60.02%10.83%3.30%
2011$2.81B$77.60M96.40%7.69%2.76%
2012$2.68B$40.30M96.42%8.25%1.50%
2013$2.82B$144.80M96.42%11.83%5.13%
2014$3.04B$157.70M96.35%11.18%5.19%
2015$2.99B$105.60M96.29%10.25%3.53%
2016$3.13B$153.40M61.39%10.84%4.91%
2017$3.20B$170.40M61.63%10.77%5.33%
2018$3.16B$112.30M96.11%8.59%3.55%
2019$0.00$-390990.00
2020$0.00$-812371.00
2021$0.00$-1.35M
2022$0.00$-7.42M
2023$0.00$-5.87M
2024$0.00$-4.30M
2025$-3.58M

Frequently asked questions

How much free cash flow does RGC generate?

RGC produced $-3.27M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is RGC's balance sheet healthy?

RGC holds $2.42M in cash and equivalents against — in long-term debt, on $4.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.